Key facts
- This page summarizes Christopher B. Ehrlich's Form 4 filing for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 09 Jan 2026, 16:30.
Christopher B. Ehrlich - 07 Jan 2026 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)
- Signature
- /s/ Andrew Kucharchuk, Attorney-in-Fact
- Issuer symbol
- CERO
- Transactions as of
- 07 Jan 2026
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 09 Jan 2026, 16:30:15 UTC
- Previous filing
- 02 Jun 2025
- SEC
- View on sec.gov
Key filing fact
Christopher B. Ehrlich filed Form 4 for CERO THERAPEUTICS HOLDINGS, INC. (CERO) on 09 Jan 2026.
Change
- Previous filing in this sequence was filed on 02 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001293973
Primary reporting owner
Ehrlich Christopher B
- Relationship
- Chairman and CEO, Director
- Address
- CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO
- Signature
- /s/ Andrew Kucharchuk, Attorney-in-Fact
- Signature date
- 09 Jan 2026
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
CERO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,530,997
- Change %
- Price
- $0.000000
- Shares after
- 4,530,997
- Date
- 07 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,530,997
- Exercise price
- $0.0550
* An asterisk sign (*) next to the price indicates that the price is likely invalid.